Home > Compound List > Product Information
RF9 trifluoroacetate salt_Molecular_structure_CAS_876310-60-0(freebase))
Click picture or here to close

RF9 trifluoroacetate salt

Catalog No. R4282 Name Sigma Aldrich
CAS Number 876310-60-0(freebase) Website http://www.sigmaaldrich.com
M. F. C28H39F3N6O5 Telephone 1-800-521-8956
M. W. 596.6416696 Fax
Purity ≥97% (HPLC) Email
Storage Chembase ID: 154322

SYNONYMS

IUPAC name
(2S)-5-carbamimidamido-N-[(1S)-1-carbamoyl-2-phenylethyl]-2-[(3R,5S,7s)-adamantan-1-ylformamido]pentanamide; trifluoroacetic acid
IUPAC Traditional name
(2S)-5-carbamimidamido-N-[(1S)-1-carbamoyl-2-phenylethyl]-2-[(3R,5S,7s)-adamantan-1-ylformamido]pentanamide; trifluoroacetic acid
Synonyms
1-Adamantanecarbonyl-Arg-Phe-NH2 trifluoroacetate salt

DATABASE IDS

CAS Number 876310-60-0(freebase)

PROPERTIES

Empirical Formula (Hill Notation) C26H38N6O3 · xC2HF3O2
Purity ≥97% (HPLC)
Solubility H2O: soluble20 mg/mL
MSDS Link Download
Personal Protective Equipment Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
Storage Temperature -20°C
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
RF9 is a neuropeptide FF receptor antagonist. NPFF is a member of the FMRFamide (Phe-Met-Arg-PheNH2) family of neuropeptides, which are implicated in nociception and regulation of opioid analgesia. NPFF exhibits antiopioid activity (hyperalgesia). NPFF antagonists are expected to improve the therapeutic efficacy of opioids for treatment of chronic pain. The affinity of RF9 for NPFF1R and NPFF2R is 58 and 75 nM, respectively. RF9 acts as a potent competitive antagonist of NPFF at NPFF2R RF9 exhibits no agonist activity in GTPgS assays.
Description (简体中文)
Biochem/physiol Actions
RF9 is a neuropeptide FF receptor antagonist. NPFF is a member of the FMRFamide (Phe-Met-Arg-PheNH2) family of neuropeptides, which are implicated in nociception and regulation of opioid analgesia. NPFF exhibits antiopioid activity (hyperalgesia). NPFF antagonists are expected to improve the therapeutic efficacy of opioids for treatment of chronic pain. The affinity of RF9 for NPFF1R and NPFF2R is 58 and 75 nM, respectively. RF9 acts as a potent competitive antagonist of NPFF at NPFF2R RF9 exhibits no agonist activity in GTPgS assays.

REFERENCES